Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)

About Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EYEG
  • CUSIP: N/A
  • Web: www.eyegatepharma.com
Capitalization:
  • Market Cap: $19.1 million
  • Outstanding Shares: 17,205,000
Average Prices:
  • 50 Day Moving Avg: $1.17
  • 200 Day Moving Avg: $1.17
  • 52 Week Range: $0.90 - $3.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.50
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $767,481.00
  • Price / Sales: 24.83
  • Book Value: $0.27 per share
  • Price / Book: 4.16
Profitability:
  • EBITDA: ($13,310,000.00)
  • Net Margins: -1,737.29%
  • Return on Equity: -840.69%
  • Return on Assets: -105.23%
Debt:
  • Current Ratio: 1.13%
  • Quick Ratio: 1.13%
Misc:
  • Average Volume: 233,125 shs.
  • Beta: 3.32
  • Short Ratio: 4.64
 

Frequently Asked Questions for Eyegate Pharmaceuticals (NASDAQ:EYEG)

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) released its quarterly earnings results on Monday, May, 8th. The company reported ($0.39) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.39). The business earned $0.19 million during the quarter, compared to analysts' expectations of $0.22 million. Eyegate Pharmaceuticals had a negative net margin of 1,737.29% and a negative return on equity of 840.69%. View Eyegate Pharmaceuticals' Earnings History.

When will Eyegate Pharmaceuticals make its next earnings announcement?

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Eyegate Pharmaceuticals.

Where is Eyegate Pharmaceuticals' stock going? Where will Eyegate Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 12 month target prices for Eyegate Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $7.33 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decrease in short interest in September. As of September 29th, there was short interest totalling 768,633 shares, a decrease of 38.0% from the September 15th total of 1,239,738 shares. Based on an average trading volume of 228,351 shares, the days-to-cover ratio is currently 3.4 days. Approximately 6.4% of the company's shares are sold short.

Who are some of Eyegate Pharmaceuticals' key competitors?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:

  • Paul G. Chaney, Chairman of the Board
  • Stephen From, President, Director
  • Sarah M. Romano, Interim Chief Financial Officer, Corporate Controller
  • Lisa Brandano, Vice President - Clinical Operations
  • Michael Manzo, Vice President - Engineering
  • Carol Assang, Director - Clinical Operations
  • Barbara Wirostko M.D., Chief Medical Officer
  • Thomas Balland, Independent Director
  • Morton F. Goldberg, Independent Director
  • Thomas E. Hancock, Independent Director

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

How do I buy Eyegate Pharmaceuticals stock?

Shares of Eyegate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of Eyegate Pharmaceuticals stock can currently be purchased for approximately $1.11.


MarketBeat Community Rating for Eyegate Pharmaceuticals (NASDAQ EYEG)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eyegate Pharmaceuticals (NASDAQ:EYEG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33 (562.03% upside)
Consensus Price Target History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Price Target History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Analysts' Ratings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
5/19/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00N/AView Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00N/AView Rating Details
6/28/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Earnings by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Earnings History by Quarter for Eyegate Pharmaceuticals (NASDAQ EYEG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.22)N/AView Earnings Details
5/8/20173/31/2017($0.39)($0.39)$0.22 million$0.19 millionViewN/AView Earnings Details
8/10/2016Q2 2016($0.31)($0.46)$0.24 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.25)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.22)($0.22)($0.22)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 12.99%
Insider Trades by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Institutional Ownership by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Insider Trades by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Sarah RomanoCFOBuy10,000$1.00$10,000.00View SEC Filing  
8/10/2017Stephen FromInsiderBuy12,500$1.03$12,875.00View SEC Filing  
3/6/2017Morton GoldbergDirectorSell8,919$3.00$26,757.00View SEC Filing  
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.00View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.00View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.00View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.09View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Latest Headlines for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to EyeGate Pharmaceuticals, Inc. : October 18, 2017
finance.yahoo.com - October 18 at 7:53 PM
americanbankingnews.com logoEyegate Pharmaceuticals, Inc. (EYEG) Short Interest Update
www.americanbankingnews.com - October 14 at 2:04 AM
americanbankingnews.com logoHead-To-Head Analysis: SCYNEXIS (SCYX) vs. Eyegate Pharmaceuticals (EYEG)
www.americanbankingnews.com - October 1 at 12:18 PM
americanbankingnews.com logoEyegate Pharmaceuticals (EYEG) versus Astrazeneca PLC (AZN) Financial Analysis
www.americanbankingnews.com - September 27 at 6:22 AM
americanbankingnews.com logo Brokerages Anticipate Eyegate Pharmaceuticals, Inc. (EYEG) Will Announce Quarterly Sales of $180,000.00
www.americanbankingnews.com - September 23 at 1:40 PM
streetinsider.com logoForm 8-K EYEGATE PHARMACEUTICALS For: Sep 12 - StreetInsider.com
www.streetinsider.com - September 13 at 12:27 AM
globenewswire.com logoEyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships - GlobeNewswire (press release)
globenewswire.com - September 12 at 12:12 AM
finance.yahoo.com logoEyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships
finance.yahoo.com - September 11 at 7:08 PM
nasdaq.com logoEyeGate Pharma to Present at the 19th Annual Rodman and Renshaw Global Investment Conference - Nasdaq
www.nasdaq.com - September 7 at 6:13 AM
americanbankingnews.com logoEyegate Pharmaceuticals, Inc. (EYEG) Expected to Post Quarterly Sales of $180,000.00
www.americanbankingnews.com - September 4 at 5:52 AM
finance.yahoo.com logoETFs with exposure to EyeGate Pharmaceuticals, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 11:33 PM
finance.yahoo.com logoEyeGate Pharmaceuticals, Inc. :EYEG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 7:41 PM
americanbankingnews.com logoInsider Buying: Eyegate Pharmaceuticals, Inc. (EYEG) Insider Purchases 12,500 Shares of Stock
www.americanbankingnews.com - August 10 at 8:52 PM
americanbankingnews.com logoBrokers Set Expectations for Eyegate Pharmaceuticals, Inc.'s Q3 2017 Earnings (NASDAQ:EYEG)
www.americanbankingnews.com - August 10 at 12:04 PM
finance.yahoo.com logoEYEG: Q2 Inline. Additional Trials Expected To Commence
finance.yahoo.com - August 9 at 6:46 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000
www.reuters.com - August 8 at 6:16 PM
finance.yahoo.com logoEyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 7 at 6:47 PM
reuters.com logoBRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study
www.reuters.com - August 2 at 12:10 AM
americanbankingnews.com logo Brokerages Expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Will Announce Quarterly Sales of $180,000.00
www.americanbankingnews.com - July 30 at 8:07 AM
americanbankingnews.com logo$180,000.00 in Sales Expected for Eyegate Pharmaceuticals, Inc. (EYEG) This Quarter
www.americanbankingnews.com - July 5 at 10:46 AM
reuters.com logoBRIEF-Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc
www.reuters.com - June 19 at 6:18 PM
reuters.com logoBRIEF-Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals
www.reuters.com - June 16 at 3:56 PM
reuters.com logoBRIEF-Empery Asset Management reports 9.22 pct passive stake in Eyegate Pharmaceuticals
www.reuters.com - June 15 at 4:21 AM
rttnews.com logoLXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite
www.rttnews.com - June 11 at 10:18 PM
streetinsider.com logoEyegate Pharma (EYEG) Offers 6.67M in Common Stock and Warrants Priced at $1.50/Shares
www.streetinsider.com - June 9 at 5:35 PM
streetinsider.com logoEyegate Pharma (EYEG) Receives Milestone Payment from Valeant (VRX) for EGP-437
www.streetinsider.com - May 23 at 4:49 PM
reuters.com logoBRIEF-EyeGate receives milestone payment from Valeant
www.reuters.com - May 23 at 4:49 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports net loss of $2.9 million
www.reuters.com - May 8 at 4:58 PM
reuters.com logoBRIEF-Eyegate files investigational device exemption for pilot study of ocular bandage gel
www.reuters.com - May 5 at 5:19 PM
reuters.com logoBRIEF-EyeGate Pharmaceuticals files for common stock offering - Reuters
www.reuters.com - April 22 at 8:55 AM
nasdaq.com logoWhy Is Valeant (VRX) Down 17.7% Since the Last Earnings Report?
www.nasdaq.com - March 31 at 5:13 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Sangamo, Eyegate ... - PR Newswire (press release)
www.prnewswire.com - March 24 at 10:22 PM
globenewswire.com logoEyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, MD and Randall J ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 10:30 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 11:20 AM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports full-year 2016 financial results - Reuters
www.reuters.com - February 23 at 10:08 PM
prnewswire.com logoValeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post ... - PR Newswire (press release)
www.prnewswire.com - February 23 at 10:08 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 23 at 5:07 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing
www.reuters.com - February 22 at 5:24 PM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoStock Futures Rise After Walmart, Home Depot Top Earnings Estimates
us.rd.yahoo.com - February 22 at 5:24 PM
thestreet.com logoDow Higher for Eighth Straight Session as Retailers Rise
us.rd.yahoo.com - February 22 at 5:24 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing - Reuters
www.reuters.com - February 22 at 9:11 AM
nasdaq.com logoMid-Afternoon Market Update: Dow Surges Over 100 Points - Nasdaq - Nasdaq
www.nasdaq.com - February 22 at 9:11 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St
biz.yahoo.com - February 8 at 5:39 PM
us.rd.yahoo.com logo4:02 pm Eyegate Pharmaceuticals appoints Sarah Romano, Corporate Controller, as interim CFO
us.rd.yahoo.com - February 7 at 6:18 PM
reuters.com logoBRIEF-EyeGate Pharmaceuticals announces executive promotions
www.reuters.com - February 7 at 3:11 AM
streetinsider.com logoEyegate Pharma (EYEG) Names Sarah Romano as Interim CFO
www.streetinsider.com - February 7 at 3:11 AM
streetinsider.com logoEyegate Pharma (EYEG) Reports Encouraging EyeGate OBG Top-Line Results from First-in-Human Pilot Trial - StreetInsider.com
www.streetinsider.com - January 31 at 10:49 PM
247wallst.com logoIs This The Beginning of EyeGate’s Rally?
247wallst.com - January 30 at 5:26 PM
reuters.com logoBRIEF-Eyegate Pharma announces positive top-line data from first-in-human pilot trial of ocular bandage gel
www.reuters.com - January 30 at 12:08 PM

Social

Chart

Eyegate Pharmaceuticals (EYEG) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.